carbocisteine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
mucolytics 4160 638-23-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • carbocisteine
  • bronchokod
  • carbocit
  • carbocysteine
  • chilvax
  • L-(Carboxymethyl)cysteine
  • lisil
  • lisomucil
  • loviscol
  • muciclar
  • mucocis
  • mucodyne
  • mucofan
  • mucolase
  • mucolex
  • mucopront
  • mucosol
  • mucotab
  • mukinyl
  • PectDrill
  • pectox
  • pulmoclase
  • reomucil
  • rhinathiol
  • rhinatiol
  • thiodril
  • transbronchin
  • carbocisteine sodium
A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.
  • Molecular weight: 179.19
  • Formula: C5H9NO4S
  • CLOGP: -2.61
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 100.62
  • ALOGS: -0.92
  • ROTB: 5

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary pain 106.20 18.47 32 7842 3458 63477690
Upper respiratory tract inflammation 80.51 18.47 24 7850 2499 63478649
Hepatic function abnormal 73.97 18.47 50 7824 37092 63444056
Amyloid arthropathy 70.56 18.47 16 7858 564 63480584
Drug ineffective 67.54 18.47 23 7851 1044742 62436406
Interstitial lung disease 63.10 18.47 56 7818 61852 63419296
Drug eruption 55.63 18.47 38 7836 28656 63452492
Lower respiratory tract infection 55.60 18.47 75 7799 132232 63348916
Platelet count decreased 53.70 18.47 69 7805 116053 63365095
Adrenal suppression 53.40 18.47 14 7860 910 63480238
Pneumonia bacterial 49.63 18.47 24 7850 9441 63471707
Pain 41.70 18.47 20 7854 740608 62740540
Pneumonia 41.05 18.47 137 7737 456630 63024518
Adjusted calcium decreased 38.65 18.47 8 7866 182 63480966
Fatigue 37.75 18.47 33 7841 887995 62593153
Asthma 37.28 18.47 61 7813 127500 63353648
Drug-induced liver injury 34.39 18.47 33 7841 40189 63440959
Infective exacerbation of bronchiectasis 33.71 18.47 8 7866 345 63480803
Asteatosis 33.69 18.47 6 7868 59 63481089
Cardiac failure 33.62 18.47 48 7826 89094 63392054
Haemoptysis 33.33 18.47 28 7846 28698 63452450
Pyrexia 32.82 18.47 130 7744 470348 63010800
Hyponatraemia 32.00 18.47 53 7821 111847 63369301
Upper gastrointestinal haemorrhage 31.95 18.47 23 7851 18829 63462319
Diarrhoea 31.71 18.47 173 7701 715193 62765955
Blood prolactin increased 31.63 18.47 13 7861 3490 63477658
Pneumonia aspiration 28.89 18.47 28 7846 34512 63446636
Palpitations 26.50 18.47 49 7825 112721 63368427
Stevens-Johnson syndrome 26.26 18.47 23 7851 24927 63456221
Lip swelling 25.64 18.47 25 7849 31038 63450110
Myopathy 24.52 18.47 16 7858 11175 63469973
Reversible cerebral vasoconstriction syndrome 24.46 18.47 10 7864 2648 63478500
Erythema multiforme 23.41 18.47 15 7859 10154 63470994
Galactorrhoea 23.19 18.47 11 7863 4144 63477004
Gastroenteritis 23.07 18.47 22 7852 26568 63454580
Hypoglycaemia 22.13 18.47 32 7842 60033 63421115
Pharyngitis 22.06 18.47 19 7855 20124 63461024
Joint swelling 21.40 18.47 7 7867 327659 63153489
Drug interaction 20.73 18.47 69 7805 229062 63252086
Constipation 20.59 18.47 68 7806 224875 63256273
Tendonitis 20.47 18.47 18 7856 19597 63461551
Sputum retention 20.40 18.47 6 7868 596 63480552
Enteritis infectious 19.58 18.47 8 7866 2116 63479032
Urine output decreased 19.56 18.47 14 7860 11356 63469792
Obesity 19.11 18.47 21 7853 29931 63451217
Pneumomediastinum 18.88 18.47 7 7867 1429 63479719

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 152.40 16.96 126 8314 65156 34883335
Hepatic function abnormal 102.11 16.96 85 8355 44278 34904213
Pneumonia aspiration 85.61 16.96 75 8365 41828 34906663
Pneumonia 81.90 16.96 231 8209 362396 34586095
Lower respiratory tract infection 79.87 16.96 64 8376 31573 34916918
Radiation inflammation 70.58 16.96 20 8420 885 34947606
Pulmonary pain 64.61 16.96 20 8420 1204 34947287
Idiopathic pulmonary fibrosis 47.15 16.96 21 8419 3513 34944978
Lung neoplasm malignant 41.36 16.96 34 8406 17361 34931130
Drug ineffective 39.05 16.96 32 8408 456719 34491772
Upper respiratory tract inflammation 39.03 16.96 15 8425 1729 34946762
Fatigue 38.33 16.96 21 8419 370632 34577859
Pneumonia bacterial 36.46 16.96 27 8413 11845 34936646
Malignant neoplasm progression 33.63 16.96 69 8371 87977 34860514
Liver disorder 32.57 16.96 40 8400 32957 34915534
Drug eruption 29.79 16.96 30 8410 19868 34928623
Paraneoplastic rash 27.49 16.96 6 8434 88 34948403
Antibody test abnormal 27.29 16.96 7 8433 211 34948280
Schizophrenia 27.26 16.96 20 8420 8646 34939845
Neutrophil count decreased 26.94 16.96 46 8394 51058 34897433
Clumsiness 25.39 16.96 11 8429 1721 34946770
Drug-induced liver injury 25.36 16.96 33 8407 28799 34919692
Somnambulism 22.15 16.96 12 8428 3060 34945431
Condition aggravated 21.83 16.96 98 8342 192098 34756393
Mouth swelling 21.51 16.96 10 8430 1846 34946645
Knee arthroplasty 20.79 16.96 16 8424 7428 34941063
Gastric mucosal lesion 20.47 16.96 7 8433 578 34947913
Dyspnoea 20.47 16.96 158 8282 376624 34571867
Hypophagia 20.35 16.96 27 8413 23995 34924496
Eye infection 20.16 16.96 12 8428 3661 34944830
Toxicity to various agents 19.73 16.96 12 8428 200350 34748141
Clonic convulsion 19.70 16.96 7 8433 647 34947844
Duodenal ulcer perforation 19.56 16.96 9 8431 1623 34946868
Inappropriate antidiuretic hormone secretion 18.67 16.96 19 8421 12734 34935757
Pneumothorax 18.60 16.96 23 8417 19069 34929422
Radiation pneumonitis 18.17 16.96 10 8430 2630 34945861
Genital pain 17.82 16.96 6 8434 472 34948019

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 199.58 15.57 174 16355 112426 79615433
Hepatic function abnormal 171.47 15.57 133 16396 72974 79654885
Pulmonary pain 158.41 15.57 52 16477 4421 79723438
Pneumonia 118.82 15.57 352 16177 659894 79067965
Upper respiratory tract inflammation 111.73 15.57 39 16490 3996 79723863
Pneumonia aspiration 105.68 15.57 97 16432 66870 79660989
Drug ineffective 95.54 15.57 53 16476 1080860 78646999
Lower respiratory tract infection 85.51 15.57 119 16410 129101 79598758
Pneumonia bacterial 77.76 15.57 49 16480 19282 79708577
Drug eruption 73.93 15.57 66 16463 43869 79683990
Radiation inflammation 73.59 15.57 20 16509 885 79726974
Fatigue 73.20 15.57 52 16477 929675 78798184
Amyloid arthropathy 62.38 15.57 16 16513 564 79727295
Platelet count decreased 61.52 15.57 129 16400 194535 79533324
Drug-induced liver injury 51.54 15.57 66 16463 66051 79661808
Idiopathic pulmonary fibrosis 49.80 15.57 22 16507 4206 79723653
Pain 48.27 15.57 45 16484 703757 79024102
Malignant neoplasm progression 45.14 15.57 92 16437 135898 79591961
Hyponatraemia 45.11 15.57 108 16421 177740 79550119
Haemoptysis 42.23 15.57 55 16474 55944 79671915
Upper gastrointestinal haemorrhage 41.57 15.57 47 16482 41333 79686526
Cardiac failure 41.40 15.57 96 16433 154746 79573113
Pyrexia 39.57 15.57 258 16271 678451 79049408
Completed suicide 39.52 15.57 3 16526 245764 79482095
Liver disorder 38.21 15.57 60 16469 72357 79655502
Adrenal suppression 36.73 15.57 13 16516 1386 79726473
Toxicity to various agents 36.57 15.57 21 16508 421519 79306340
Neutrophil count decreased 35.33 15.57 67 16462 93892 79633967
Asthma 35.28 15.57 83 16446 135012 79592847
Stevens-Johnson syndrome 35.18 15.57 42 16487 39124 79688735
Drug hypersensitivity 33.80 15.57 10 16519 298906 79428953
Febrile convulsion 33.50 15.57 11 16518 935 79726924
Pneumothorax 33.39 15.57 35 16494 28288 79699571
Adjusted calcium decreased 33.21 15.57 8 16521 217 79727642
Lung neoplasm malignant 32.15 15.57 34 16495 27758 79700101
Dyspnoea 29.67 15.57 289 16240 856736 78871123
Asthenia 29.20 15.57 38 16491 511651 79216208
Tendonitis 29.08 15.57 30 16499 23800 79704059
Knee arthroplasty 28.82 15.57 40 16489 43208 79684651
Erythema multiforme 28.66 15.57 26 16503 17625 79710234
Paraneoplastic rash 28.40 15.57 6 16523 88 79727771
Constipation 28.35 15.57 125 16404 282925 79444934
Infective exacerbation of chronic obstructive airways disease 28.07 15.57 13 16516 2771 79725088
Sputum retention 28.07 15.57 10 16519 1087 79726772
Pneumomediastinum 27.55 15.57 14 16515 3653 79724206
Lip swelling 27.50 15.57 38 16491 40873 79686986
Asteatosis 27.46 15.57 6 16523 104 79727755
Infusion related reaction 27.34 15.57 7 16522 230230 79497629
Sputum increased 27.26 15.57 15 16514 4598 79723261
Hyperuricaemia 26.61 15.57 21 16508 11778 79716081
Orthostatic hypotension 26.18 15.57 44 16485 56120 79671739
Diarrhoea 25.31 15.57 286 16243 880203 78847656
Weight increased 25.23 15.57 13 16516 277373 79450486
Pharyngitis 25.22 15.57 27 16502 22348 79705511
Disseminated intravascular coagulation 25.16 15.57 34 16495 35808 79692051
Enterocolitis 24.79 15.57 22 16507 14490 79713369
Lymphangiosis carcinomatosa 24.70 15.57 11 16518 2143 79725716
Cerebral infarction 24.30 15.57 38 16491 45638 79682221
Altered state of consciousness 24.07 15.57 37 16492 43785 79684074
Weight decreased 23.94 15.57 23 16506 355175 79372684
Radiation pneumonitis 23.82 15.57 13 16516 3920 79723939
Nephrotic syndrome 23.31 15.57 19 16510 11155 79716704
Malaise 22.52 15.57 176 16353 489693 79238166
Gastric mucosal lesion 21.81 15.57 8 16521 945 79726914
Schizophrenia 21.72 15.57 21 16508 15419 79712440
Paraesthesia 21.63 15.57 5 16524 176318 79551541
Joint swelling 21.49 15.57 17 16512 288629 79439230
Therapeutic product effect decreased 21.44 15.57 4 16525 163859 79564000
Arthralgia 21.42 15.57 55 16474 571748 79156111
Fixed eruption 21.39 15.57 11 16518 2943 79724916
Blood prolactin increased 20.87 15.57 12 16517 3999 79723860
Bronchitis 20.83 15.57 67 16462 130577 79597282
Clumsiness 20.80 15.57 11 16518 3116 79724743
Chronic obstructive pulmonary disease 20.70 15.57 51 16478 85368 79642491
Antibody test abnormal 20.52 15.57 7 16522 669 79727190
Hypophagia 20.42 15.57 35 16494 45332 79682527
Rheumatoid arthritis 20.13 15.57 9 16520 208461 79519398
Enteritis infectious 20.12 15.57 11 16518 3327 79724532
Zinc deficiency 19.64 15.57 5 16524 171 79727688
Clonic convulsion 19.63 15.57 8 16521 1254 79726605
Melaena 18.78 15.57 40 16489 60850 79667009
Treatment failure 18.72 15.57 6 16523 170480 79557379
Pneumothorax spontaneous 18.53 15.57 8 16521 1446 79726413
Palpitations 18.46 15.57 63 16466 126547 79601312
Duodenal perforation 18.41 15.57 9 16520 2163 79725696
Fulminant type 1 diabetes mellitus 18.38 15.57 8 16521 1475 79726384
Reversible cerebral vasoconstriction syndrome 18.23 15.57 10 16519 3047 79724812
Non-small cell lung cancer 18.08 15.57 13 16516 6347 79721512
Myositis 17.95 15.57 21 16508 19147 79708712
Laryngopharyngitis 17.77 15.57 4 16525 80 79727779
Productive cough 17.58 15.57 49 16480 88282 79639577
Pulmonary alveolar haemorrhage 16.90 15.57 16 16513 11441 79716418
Delirium 16.89 15.57 47 16482 84580 79643279
Respiratory failure 16.68 15.57 78 16451 180833 79547026
Galactorrhoea 16.59 15.57 10 16519 3636 79724223
Mouth swelling 16.36 15.57 12 16517 6039 79721820
Gastroenteritis 16.28 15.57 27 16502 34055 79693804
Abnormal behaviour 16.26 15.57 28 16501 36393 79691466
Infective exacerbation of bronchiectasis 15.89 15.57 6 16523 768 79727091
Genital pain 15.60 15.57 6 16523 808 79727051

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05CB03 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000891 Anti-Infective Agents, Local
MeSH PA D005100 Expectorants
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:77034 mucolytics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Gastrointestinal ulcer contraindication 40845000
Gastrointestinal hemorrhage contraindication 74474003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.15 acidic
pKa2 2.79 acidic
pKa3 9.51 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000170286 NUI
D06393 KEGG_DRUG
C0006992 UMLSCUI
CHEBI:16163 CHEBI
CAY PDB_CHEM_ID
CCS PDB_CHEM_ID
CHEMBL396416 ChEMBL_ID
DB04339 DRUGBANK_ID
193653 PUBCHEM_CID
2023 RXNORM
26469 MMSL
d05062 MMSL
003677 NDDF
395842001 SNOMEDCT_US
772923009 SNOMEDCT_US
D002233 MESH_DESCRIPTOR_UI
2884 INN_ID
740J2QX53R UNII

Pharmaceutical products:

None